Qvanteq is a medtech startup company, developing novel bioactive stents to address and overcome the clinical adverse effects of today’s available coronary and endovascular stents. Its bioactive Qstent controls in-growth therefore reducing the risk of restenosis and thrombosis. The company was awarded with the CTI start-up label in 2012. Qvanteq was founded in 2009 and is held by private investors. The ISO 13485 certified company is based in Zürich, Switzerland. It is a spin-off company from the Swiss Federal Institute of Technology, Zurich.